Title: Regulatory Issues
1Regulatory Issues Clinical Trials A Focus on
Europe
MassMEDIC International Marketing Seminar 27
February 2004
Waltham, Mass.
Maria E. Donawa, M.D. President, Donawa
Associates Ltd.
2 Purpose of this presentation
To provide an overview of European regulatory
and clinical investigation requirements and
issues, which should be considered and addressed
during international product introduction
planning
3European regulatory fundamentals
- Understand the basic principals of European
regulation and how to access information on these
requirements, which are currently evolving - Realize that European regulatory harmonization
has not removed all country-to-country
differences (e.g., registration, labeling,
clinical investigation) - Be aware that conducting clinical studies in
Europe may be less costly and burdensome, but
require knowledge of European regulatory and
investigational site requirements
4European Single Market
- European Community (EC) Treaty of Rome, 1957
- European Union (EU)
- Austria, Belgium, Denmark, Finland, France,
Germany, Greece, Ireland, Italy, Luxembourg,
Netherlands, Portugal, Spain, Sweden, United
Kingdom - New members as of 1 May 2004
- Cyprus, the Czech Republic, Estonia, Hungary,
Latvia, Lithuania, Malta, Poland, Slovakia and
Slovenia - European Free Trade Association (EFTA)
- Iceland, Liechtenstein, Norway, Switzerland
- European Economic Area (EEA)
- EU Iceland, Liechtenstein, Norway
- Switzerland
- EU-Switzerland bilateral trade / mutual
recognition agreements
5Principles of New Approach Directives
- New Approach introduced by Council Resolution of
May 1985 - Directives contain a list of Essential
Requirements (ERs) - Detailed technical provisions in harmonized
standards adopted by European standards
organizations (CEN, CENELEC) - Harmonized standards are voluntary, but confer
presumption of conformity with the relevant ERs - Directives are not directly legally binding. They
must be transposed into national laws
regulations - Products that comply with the Directives are
affixed with the CE mark and can circulate
throughout the EEA
6European Directives
- Active Implantable Medical Device Directive
(90/385/EEC) - Medical Device (MD) Directive (93/42/EEC)
- In Vitro Diagnostic (IVD) Medical Device
Directive (98/79/EEC) - Directive on Medical Devices Incorporating Human
Blood and Human Plasma (2000/70/EC) - Council Directive 2003/32/EC of 23 April 2003
- specifies mandatory requirements for medical
devices using non-viable animal tissue
7 European Directives
- Requirements apply to
- Manufacturers
- Competent authorities
- government body in each Member State responsible
for implementing and enforcing the Directives - Notified bodies
- designated by competent authorities to perform
one or more of the conformity assessment
procedures for devices in class I that are
sterile or have a measuring function class IIa,
class IIb, and class III - Authorized representatives
- defined in Article 1(2)(j) designated by
manufacturers to act or be addressed by
authorities and bodies in the EC
8MD Directive Classification
- Depends upon
- risk, duration of use, invasiveness, anatomy
affected by use of the device, whether or not
device is active or non-active - Determines conformity assessment options
- Annex IX - 18 classification rules
- Four classes, increasing in risk from class I to
III - Class I - hospital beds, corrective glasses
- Class IIa - syringes for infusion pumps,
- Class IIb - hemodialyzers
- Class III - angioplasty balloon catheters
- Classification guidance document
9Conformity Assessment
- Manufacturers can demonstrate conformity through
- testing alone
- testing plus quality system certification
- quality system certification alone
- Most common methods are
- certification of full quality assurance
- EC Type-Examination (product testing) plus
certification of production quality assurance,
and - for class I devices, self-declaration procedure
10Risk Analysis Risk Management
- European Directives for medical devices require
risk analysis for all devices -
- Important part of Technical File or Design
Dossier - EN ISO 14971, Medical devices Application of
risk management to medical devices - Applied to the medical device
11Adverse event reporting
- Any malfunction or deterioration in the
characteristics and/or performance of a device or
any inadequacy in the labelling or instructions
for use - which might lead to (near incident) or
- might have led (incident) to the death of a
patient or user or to a serious deterioration in
state of health - Any technical or medical reason in relation to
the characteristics or performance of a device
for the reasons stated above leading to
systematic recall
12Adverse event reporting
- Similarities differences between European and
US Medical Device Reporting requirements - Reporting timeframes differ
- Terminology differs
- US FDA requires that unanticipated adverse
events that occur during clinical investigations
be reported - Therefore, specific procedures for meeting
European adverse event requirements should be
developed
13National regulatory variations
- Medical device registration under Article 14 of
the MD Directive some countries require
registration of - only class I and custom-made devices (UK)
- class I, custom-made, and higher risk devices
(France) - all devices regardless of class (Italy)
- Labelling some Member States allow labelling
and instructions for use in English, while others
require local language - Clinical investigation notification some Member
States require Ethics Committee approval before
notification to the Competent Authority
(regulatory authority) and some do not
14European harmonized standards
- EN ISO 134852000, Quality systems - Medical
devices - Particular requirements for the
application of EN ISO 90011994 - EN ISO 134882000, Quality systems Medical
devices - Particular requirements for the
application of ISO 90021994 - EN ISO 14155-12003 Clinical investigation of
medical devices for human subjects - Part 1
General requirements - EN ISO 14155-22003 Clinical investigation of
medical devices for human subjects - Part 2
Clinical investigation plans - EN 375 2001, Information supplied by the
manufacturer with in vitro diagnostic reagents
for professional use - EN 455-1 Medical gloves for single use - Part 1
Requirements and testing for freedom from holes - Many others
15European guidance
- Guidelines for the Classification of Medical
Devices (MEDDEV 2.4/1 Rev.8, July 2001) - Guidelines on a Medical Devices Vigilance System
(MEDDEV 2.12-1 rev 4, April 2001) - Demarcation between medical devices and medicinal
products (MEDDEV 2. 1/3 rev 2, July 2001) - Evaluation of Clinical Data, A Guide for
Manufacturers and Notified Bodies (MEDDEV 2.7.1,
April 2003) - Medical Devices Utilizing Tissues or Derivatives
Originating from Animals for Which a TSE Risk Is
Suspected A Guide For Manufacturers and
Notified Bodies (MEDDEV. 2.11/1 rev.1, February
2004) - Over 20 guidance documents
- issued by the European Commission
16Technical documentation
- Required for all devices, regardless of device
class - Includes
- Declaration of conformity
- Documentation required by conformity assessment
route - Documentation of conformity with applicable
Essential Requirements - Results of Risk Analysis
- Results of clinical investigation or literature
review - If applicable, statement for devices for clinical
investigation or custom devices
17Major Steps in CE Marking Process
- Determine if product is a medical device
- Identify applicable Directive
- Identify likely conformity assessment route
(e.g., Annex II) - Identify applicable Essential Requirements (ERs)
- Identify relevant harmonized standards, EP
monographs, other standards - Conduct risk analysis plan risk management
18Major Steps in CE Marking Process
- Determine clinical evaluation needs (scientific
literature or clinical investigation) - Select Notified Body, if necessary
- Comply with ERs and standards and follow
conformity assessment procedures - Select Authorized Representative, if appropriate
or required - Ensure that Technical File is complete, accurate
and controlled - Draw up declaration of conformity and apply CE
mark
19European Commission Website
http//europa.eu.int/comm/enterprise/medical_devic
es/index.htm
20Clinical Investigation Requirements
- The requirements for conducting European clinical
investigations are becoming more stringent due to
- a perceived lack of adequate clinical data to
support some device safety and performance claims - inadequate expertise for evaluating clinical data
within some Notified Body organizations - sufficiently detailed guidance documents for
clinical investigations involving some types of
products
21Clinical Investigation Requirements
- Article 15, Clinical investigation (MD Directive)
- Must follow procedure in Annex VIII, Statement
concerning Devices for Special Purposes - Must notify Competent Authority
- Sixty-day waiting period for some categories of
devices (requirement differs somewhat among
Member States) - Must conduct investigation in accordance with
Annex X, Clinical evaluation - EN ISO 14155-12003, Clinical investigation of
medical devices for human subjects Part 1
General requirements - EN ISO 14155-22003 Clinical investigation of
medical devices for human subjects - Part 2
Clinical investigation plans
22Clinical investigation guidance
- Check for existence of national guidance
documents - E.g., UK Medicines and Healthcare products
Regulatory Agency (MHRA) guidance documents and
forms - Information for Clinical Investigators (UK)
- Guidance for Manufacturers on Clinical
Investigations to be Carried Out in the UK - Pre-Clinical Assessment (PCA) Forms, PCA1 and
PCA2 - Evaluation of Clinical Data, A Guide for
Manufacturers and Notified Bodies (MEDDEV 2.7.1,
April 2003)
23 Clinical investigation standards
- EN ISO 14155-12003 Clinical investigation of
medical devices for human subjects - Part 1
General requirements - harmonized standard that ensures that clinical
study requirements in the Directives are met - EN ISO 14155-22003 Clinical investigation of
medical devices for human subjects - Part 2
Clinical investigation plans - harmonized standard that specifies the content,
review, and control of the clinical investigation
plan (CIP or protocol)
24 Conducting successful
European clinical studies
- Evaluate and select investigational sites in a
formal manner to ensure that the site can fulfil
study requirements and has the capability of
recruiting adequate numbers of patients - Conduct on-site training to ensure that
investigators, site support personnel, and
monitors understand company procedures,
regulatory requirements, and good clinical
practice principles - Develop easy-to-understand and convincing study
materials for regulators, ethics committees, and
investigators to aid in the acceptance of the
study
25Questions?
Maria E. Donawa, M.D. President Donawa
Associates Ltd. Via Fonte di Fauno, 22 ? 00153
Rome, Italy 39 06 578 2665 ? FAX 39 06 574
3786 donawa_at_srd.it ? www.donawa.com